New wrinkle treatment AGN-151586 tested in japanese adults

NCT ID NCT06151561

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested an investigational botulinum toxin injection called AGN-151586 for moderate to severe frown lines (glabellar lines) in 24 Japanese adults. Participants received either the active drug or a placebo, and researchers measured wrinkle improvement and safety over about 6 weeks. The goal is to see if this treatment is safe and effective for this population.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

AGN-151586 (botulinum toxin injection)

What this could lead to

If it works, this could offer a safe and effective option for reducing frown lines in Japanese adults.

What could go wrong

This is a very early, small Phase 1/2 trial with only 24 participants. The results may not apply to everyone, and side effects or lack of effect are possible.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MODERATE TO SEVERE GLABELLAR LINES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Tokyo Center Clinic /ID# 257898

    Central District, Tokyo, 103-0028, Japan